[go: up one dir, main page]

CN116113628A - A kind of pharmaceutical composition containing CDK4/6 inhibitor - Google Patents

A kind of pharmaceutical composition containing CDK4/6 inhibitor Download PDF

Info

Publication number
CN116113628A
CN116113628A CN202180053613.XA CN202180053613A CN116113628A CN 116113628 A CN116113628 A CN 116113628A CN 202180053613 A CN202180053613 A CN 202180053613A CN 116113628 A CN116113628 A CN 116113628A
Authority
CN
China
Prior art keywords
pharmaceutical composition
inhibitor
composition containing
fluoro
cdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053613.XA
Other languages
Chinese (zh)
Inventor
尹磊
姚郑林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of CN116113628A publication Critical patent/CN116113628A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising 5-fluoro-4- (7 '-fluoro-2' -methyl spiro [ cyclopentane-1, 3 '-indol ] -5' -yl) -N- (5- (1-methylpiperidin-4-yl) pyridin-2-yl) pyrimidin-2-amine or a pharmaceutically acceptable salt thereof as an active ingredient and a diluent. The pharmaceutical composition has rapid dissolution, improved solubility, stability, flowability, reduced hygroscopicity and risk of food effect, and stable and controllable quality. In addition, the preparation formula of the pharmaceutical composition has simple process and is more suitable for industrial mass production.

Description

PCT国内申请，说明书已公开。PCT domestic application, specification has been published.

Claims (21)

PCT国内申请，权利要求书已公开。PCT domestic application, the claims have been published.
CN202180053613.XA 2020-08-31 2021-08-31 A kind of pharmaceutical composition containing CDK4/6 inhibitor Pending CN116113628A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010893836 2020-08-31
CN2020108938364 2020-08-31
PCT/CN2021/115486 WO2022042738A1 (en) 2020-08-31 2021-08-31 Pharmaceutical composition containing cdk4/6 inhibitor

Publications (1)

Publication Number Publication Date
CN116113628A true CN116113628A (en) 2023-05-12

Family

ID=80354702

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053613.XA Pending CN116113628A (en) 2020-08-31 2021-08-31 A kind of pharmaceutical composition containing CDK4/6 inhibitor

Country Status (2)

Country Link
CN (1) CN116113628A (en)
WO (1) WO2022042738A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (en) * 2015-11-30 2017-06-09 甘李药业股份有限公司 A kind of kinases inhibitor and preparation method thereof and medical usage
CN107405350A (en) * 2016-02-04 2017-11-28 江苏恒瑞医药股份有限公司 A kind of pharmaceutical composition containing pyridopyrimidines derivatives or its officinal salt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617622T3 (en) * 2008-02-15 2017-06-19 Rigel Pharmaceuticals, Inc. Pyrimidin-2-amine compounds and their use as inhibitors of JAK kinases
PA8852901A1 (en) * 2008-12-22 2010-07-27 Lilly Co Eli PROTEIN CINASE INHIBITORS
AR119184A1 (en) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals SALTS OF A COMPOUND, CRYSTALLINE FORMS OF THE SALTS AND METHOD OF PREPARATION AND USE OF THE SAME

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (en) * 2015-11-30 2017-06-09 甘李药业股份有限公司 A kind of kinases inhibitor and preparation method thereof and medical usage
CN107405350A (en) * 2016-02-04 2017-11-28 江苏恒瑞医药股份有限公司 A kind of pharmaceutical composition containing pyridopyrimidines derivatives or its officinal salt

Also Published As

Publication number Publication date
WO2022042738A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
RU2744432C2 (en) Pharmaceutical composition including janus kinase inhibitor or pharmaceutically acceptable salt thereof
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
JP2006512314A (en) Use of the compositions as JAK inhibitors and other protein kinase inhibitors
CN101743246B (en) 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents
CA2451981A1 (en) 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
AU2014295143B9 (en) Salts of Dasatinib in amorphous form
JP2006524688A (en) Thiazoles useful as protein kinase inhibitors
MY146669A (en) Pyrazole derivatives for treating hiv
JP2016540803A5 (en)
JP2021167346A5 (en)
ZA202106437B (en) Compound form having enhanced bioavailability and formulations thereof
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CN116113628A (en) A kind of pharmaceutical composition containing CDK4/6 inhibitor
CN111936467A (en) Crystal of compound as c-Met kinase inhibitor and preparation method and application thereof
AU2003263498A1 (en) Pyrazole derivatives
JP2003012667A (en) Antimicrobial agent having quinolin carboxamide skelton
WO2005120516A3 (en) Hiv integrase inhibitors
WO2007050510A3 (en) Hiv integrase inhibitors
AU2006299042A8 (en) HIV integrase inhibitors
DE602006015291D1 (en) HIV-INHIBITED 2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINE
JP2008524335A5 (en)
CN111303046B (en) Biphenyl diarylpyrimidine derivatives containing chiral hydroxymethylene structure and preparation method and use thereof
ATE386741T1 (en) PYRAZOLAMIDE FOR THE TREATMENT OF HIV INFECTIONS
WO2020221894A1 (en) Antiviral compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination